# iRegene AI and chemically induced cell drug research and development. Canonical: https://uniquebase.ai/companies/UB-C5987 Stable identifier: UB-C5987 Snapshot captured: 2026-10-15T14:23:27.067Z English updated: 2026-10-15T20:20:54.784Z ## Funding Listed 7 records. Latest: RMB 260M (Series C+), 2026-07-02. - 2026-08-18 · Undisclosed · Equity · Wuxi City Biotechnology Pharmaceutical Industry Fund (Limited Partnership), 上海鼎泰星科技发展有限公司, 四川省成果转化投资引导基金合伙企业（有限合伙）, 成都弘生一期创业投资合伙企业（有限合伙）, 成都未来产业创业投资发展基金合伙企业（有限合伙）, 深圳市鹏远基石私募股权投资基金合伙企业（有限合伙） > On 2026-08-18, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Sichuan Shengchengguozhuanhua Investment Yindao Fund Partnership (Limited Partnership), Chengdu Hongsheng Phase One Venture Capital Partnership (Limited Partnership), Wuxi City Biotechnology Pharmaceutical Industry Fund (Limited Partnership), Shenzhen City Pengyuanjishi Private Equity Investment Fund Partnership (Limited Partnership), Chengdu Weilai Industry Venture Capital Development Fund Partnership (Limited Partnership), Shanghai Dingtaixing Technology Development Co., Ltd.. The company is a developer of chemically induced cell therapy drugs. (translated source brief) - 2026-07-14 · Undisclosed · Equity · 苏州杏泽兴涌新兴医疗产业投资基金管理合伙企业（有限合伙） > On 2026-07-14, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Suzhou Xingzexingyongxinxing Medical Industrial Investment Fund Management Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs. (translated source brief) - 2026-07-02 · RMB 260M (≈ $37.1M) · Series C+ · 中信建投资本, 元希海河（天津）生物医药产业基金合伙企业（有限合伙）, 弘毅资本, 成都科创投, 新基业, 锡创投, 鼎泰星 > On 2026-07-02, according to Xiniu Data, iRegene completed Series C+ financing, raising RMB 260 million. Investors were lead investor Chengdu Ke Venture Capital, participating investor Zhongxinjian Investment Ben, participating investor Xi Venture Capital, participating investor Dingtaixing, participating investor Xinjiye, participating investor Hongyi Capital, participating investor Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs. (translated source brief) - 2026-04-27 · RMB 210M (≈ $30M) · Series C · 杏泽资本 > On 2026-04-27, according to Xiniu Data, iRegene completed Series C financing, raising RMB 210 million. Investors were co-lead investor Nantongheyuanyihao Venture Capital Partnership (Limited Partnership), co-lead investor Xingze Capital. The company is a developer of chemically induced cell therapy drugs. (translated source brief) - 2026-03-30 · Undisclosed · Equity · 关子创投, 北极光创投, 荷慧生物 > On 2026-03-30, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Beijiguang Venture Capital, Guanzi Venture Capital, Hehui Biotechnology. (translated source brief) - 2026-03-19 · Undisclosed · Equity · 祥峰投资 > On 2026-03-19, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Xiangfeng Investment. (translated source brief) - 2025-09-04 · RMB 100M (≈ $14.3M) · Series B · 创景资本, 北极光创投, 金沙江联合资本 ## Valuation Listed 7 records. - 2026-08-18 · amount unavailable · Equity · Wuxi City Biotechnology Pharmaceutical Industry Fund (Limited Partnership), 上海鼎泰星科技发展有限公司, 四川省成果转化投资引导基金合伙企业（有限合伙）, 成都弘生一期创业投资合伙企业（有限合伙）, 成都未来产业创业投资发展基金合伙企业（有限合伙）, 深圳市鹏远基石私募股权投资基金合伙企业（有限合伙） > On 2026-08-18, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Sichuan Shengchengguozhuanhua Investment Yindao Fund Partnership (Limited Partnership), Chengdu Hongsheng Phase One Venture Capital Partnership (Limited Partnership), Wuxi City Biotechnology Pharmaceutical Industry Fund (Limited Partnership), Shenzhen City Pengyuanjishi Private Equity Investment Fund Partnership (Limited Partnership), Chengdu Weilai Industry Venture Capital Development Fund Partnership (Limited Partnership), Shanghai Dingtaixing Technology Development Co., Ltd.. The company is a developer of chemically induced cell therapy drugs. (translated source brief) - 2026-07-14 · amount unavailable · Equity · 苏州杏泽兴涌新兴医疗产业投资基金管理合伙企业（有限合伙） > On 2026-07-14, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Suzhou Xingzexingyongxinxing Medical Industrial Investment Fund Management Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs. (translated source brief) - 2026-07-02 · amount unavailable · Series C+ · 中信建投资本, 元希海河（天津）生物医药产业基金合伙企业（有限合伙）, 弘毅资本, 成都科创投, 新基业, 锡创投, 鼎泰星 > On 2026-07-02, according to Xiniu Data, iRegene completed Series C+ financing, raising RMB 260 million. Investors were lead investor Chengdu Ke Venture Capital, participating investor Zhongxinjian Investment Ben, participating investor Xi Venture Capital, participating investor Dingtaixing, participating investor Xinjiye, participating investor Hongyi Capital, participating investor Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs. (translated source brief) - 2026-04-27 · amount unavailable · Series C · 杏泽资本 > On 2026-04-27, according to Xiniu Data, iRegene completed Series C financing, raising RMB 210 million. Investors were co-lead investor Nantongheyuanyihao Venture Capital Partnership (Limited Partnership), co-lead investor Xingze Capital. The company is a developer of chemically induced cell therapy drugs. (translated source brief) - 2026-03-30 · amount unavailable · Equity · 关子创投, 北极光创投, 荷慧生物 > On 2026-03-30, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Beijiguang Venture Capital, Guanzi Venture Capital, Hehui Biotechnology. (translated source brief) - 2026-03-19 · amount unavailable · Equity · 祥峰投资 > On 2026-03-19, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Xiangfeng Investment. (translated source brief) - 2025-09-04 · amount unavailable · Series B · 创景资本, 北极光创投, 金沙江联合资本 ## Revenue No revenue records are listed yet. ## Team No published team profiles are linked yet. ## Products No published products profiles are linked yet. ## Investors - [Wuxi City Biotechnology Pharmaceutical Industry Fund (Limited Partnership)](/institutions/wuxi-city-biotechnology-pharmaceutical-industry-fund-limited-partnership) - [上海鼎泰星科技发展有限公司](/institutions/shanghai-dingtaixing-technology-development-co-ltd) - [中信建投资本](/institutions/zhongxinjian-investment-ben) - [元希海河（天津）生物医药产业基金合伙企业（有限合伙）](/institutions/yuanxihaihe-tianjin-biotechnology-pharmaceutical-industry-fund-partnership-limited-partnership) - [关子创投](/institutions/guanzi-venture-capital) - [创景资本](/institutions/chuangjing-capital) - [北极光创投](/institutions/beijiguang-venture-capital) - [四川省成果转化投资引导基金合伙企业（有限合伙）](/institutions/sichuan-shengchengguozhuanhua-investment-yindao-fund-partnership-limited-partnership) - [弘毅资本](/institutions/UB-I8645) - [成都弘生一期创业投资合伙企业（有限合伙）](/institutions/chengdu-hongsheng-phase-one-venture-capital-partnership-limited-partnership) - [成都未来产业创业投资发展基金合伙企业（有限合伙）](/institutions/chengdu-weilai-industry-venture-capital-development-fund-partnership-limited-partnership) - [成都科创投](/institutions/chengdu-ke-venture-capital) - [新基业](/institutions/xinjiye) - [杏泽资本](/institutions/xingze-capital) - [深圳市鹏远基石私募股权投资基金合伙企业（有限合伙）](/institutions/shenzhen-city-pengyuanjishi-private-equity-investment-fund-partnership-limited-partnership) - [祥峰投资](/institutions/xiangfeng-investment) - [苏州杏泽兴涌新兴医疗产业投资基金管理合伙企业（有限合伙）](/institutions/suzhou-xingzexingyongxinxing-medical-industrial-investment-fund-management-partnership-limited-partnership) - [荷慧生物](/institutions/hehui-biotechnology) - [金沙江联合资本](/institutions/jinshajianglianhe-capital) - [锡创投](/institutions/xi-venture-capital) - [鼎泰星](/institutions/dingtaixing) ## Sources - No source links are available for this profile.